Top Abstract Purchase Related
Home
>
Node
>
Subnode

Treatment of sex offenders with medroxyprogesterone acetate

Gagné, P.

American Journal of Psychiatry 138(5): 644-646

1981

ISSN/ISBN: 0002-953X
PMID: 6453536
DOI: 10.1176/ajp.138.5.644
Document Number: 393001
Forty-eight male patients with long-standing histories of deviant sexual behavior received medroxyprogesterone acetate and milieu therapy for up to 12 months. Forty subjects responded positively, all within 3 weeks, with diminished frequency of sexual fantasies and arousal, decreased desire for deviant sexual behavior, increased control over sexual urges, and improvement in psychosocial functioning. Improvement in deviant sexual behavior and psychosocial functioning was maintained after treatment ended, and there was no evidence of permanent physiological changes. The author suggests that medroxyprogesterone acetate associated with counseling may be the treatment of choice for patients with long-term deviant sexual behavior. He discusses the ethical issues involved.

Document emailed within 0-6 h
Secure & encrypted payments

Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Astedt, B. 1972: Fibrinolytic activity of veins during treatment with medroxyprogesterone acetate Acta Obstetricia et Gynecologica Scandinavica 51(3): 283-286
Africander, D.J.; Storbeck, K.-H.; Hapgood, J.P. 2014: A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) Journal of Steroid Biochemistry and Molecular Biology 143: 404-415
Cooper, A.J.; Sandhu, S.; Losztyn, S.; Cernovsky, Z. 1992: A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37(10): 687-693
Arowojolu, A.O. 2000: Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience African Journal of Medicine and Medical Sciences 29(1): 55-58
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Tomasicchio, M.; Avenant, C.; Du Toit, A.; Ray, R.M.; Hapgood, J.P. 2013: The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor PLOS one 8(5): E62895
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Africander, D.; Louw, R.; Verhoog, N.; Noeth, D.; Hapgood, J.P. 2011: Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract Contraception 84(4): 423-435
Govender, Y.; Avenant, C.; Verhoog, N.J.D.; Ray, R.M.; Grantham, N.J.; Africander, D.; Hapgood, J.P. 2014: The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor Plos one 9(5): E96497
Cohen, C.J.; Deppe, G.; Bruckner, H.W. 1977: Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study Obstetrics and Gynecology 50(4): 415-417
van Milligen de Wit, A.W.; Meilof-Planteydt, M.N. 1990: Successful treatment of pulmonary lymphangioleiomyomatosis with oophorectomy and medroxyprogesterone-acetate: report of a case and brief review of the literature Netherlands Journal of Medicine 36(5-6): 246-251
Riippa, P.; Kauppila, A.; Sundström, H.; Vihko, R. 1984: Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma Anticancer Research 4(3): 109-112
Sasagawa, I.; Satomi, S.; Katayama, T. 1989: Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma Gan no Rinsho. Japan Journal of Cancer Clinics 35(6): 767-771
Toi, M.; Taniguchi, T.; Hayashi, K.; Tominaga, T. 1995: The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 799-804
Barnes, R.B.; Roy, S.; Lobo, R.A. 1985: Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women Obstetrics and Gynecology 66(2): 216-219
Goshtasebi, A.; Moukhah, S.; Gandevani, S.B. 2013: Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid Archives of Gynecology and Obstetrics 288(5): 1055-1060
Kim, M.K.; Seong, S.J.; Kim, Y.S.; Song, T.; Kim, M.-L.; Yoon, B.S.; Jun, H.S.; Lee, Y.H. 2013: Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer American Journal of Obstetrics and Gynecology 209(4): 358.E1-4